Patrick Michael Murphy Sells 400 Shares of DexCom, Inc. (DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) SVP Patrick Michael Murphy sold 400 shares of DexCom stock in a transaction that occurred on Friday, February 8th. The shares were sold at an average price of $142.76, for a total transaction of $57,104.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Patrick Michael Murphy also recently made the following trade(s):

  • On Thursday, January 10th, Patrick Michael Murphy sold 400 shares of DexCom stock. The shares were sold at an average price of $138.75, for a total transaction of $55,500.00.
  • On Monday, December 10th, Patrick Michael Murphy sold 400 shares of DexCom stock. The shares were sold at an average price of $121.90, for a total transaction of $48,760.00.

DXCM stock opened at $152.73 on Wednesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43. DexCom, Inc. has a fifty-two week low of $53.30 and a fifty-two week high of $155.85. The company has a market capitalization of $12.93 billion, a P/E ratio of -263.33 and a beta of 0.84.

A number of research firms have recently issued reports on DXCM. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Saturday, November 10th. Jefferies Financial Group lifted their target price on shares of DexCom to $148.00 and gave the company a “buy” rating in a research note on Wednesday, November 7th. Stephens lifted their target price on shares of DexCom from $170.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, November 7th. Piper Jaffray Companies boosted their price objective on shares of DexCom to $157.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 7th. Finally, Oppenheimer set a $150.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Seven equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. DexCom presently has a consensus rating of “Buy” and an average price target of $143.53.

A number of hedge funds have recently bought and sold shares of the stock. Prudential Financial Inc. raised its position in shares of DexCom by 2.2% during the 4th quarter. Prudential Financial Inc. now owns 4,668 shares of the medical device company’s stock valued at $559,000 after acquiring an additional 100 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of DexCom by 1.6% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 8,293 shares of the medical device company’s stock valued at $994,000 after acquiring an additional 131 shares during the last quarter. First Hawaiian Bank raised its position in shares of DexCom by 75.6% during the 4th quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock valued at $47,000 after acquiring an additional 170 shares during the last quarter. Marble Harbor Investment Counsel LLC raised its position in shares of DexCom by 0.5% during the 4th quarter. Marble Harbor Investment Counsel LLC now owns 34,840 shares of the medical device company’s stock valued at $4,174,000 after acquiring an additional 180 shares during the last quarter. Finally, Laurel Wealth Advisors LLC bought a new stake in shares of DexCom during the 4th quarter valued at $26,000.

COPYRIGHT VIOLATION NOTICE: “Patrick Michael Murphy Sells 400 Shares of DexCom, Inc. (DXCM) Stock” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.com-unik.info/2019/02/13/patrick-michael-murphy-sells-400-shares-of-dexcom-inc-dxcm-stock.html.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Article: Short Selling Stocks, A Beginner’s Guide

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit